Association analysis of the glycogen synthase kinase-3 beta gene in bipolar disorder

N Nishiguchi, G Breen, C Russ, D St Clair, D Collier

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Glycogen synthase kinase-3 beta (GSK3 beta) is a target of lithium as well as sodium valproate, both of which are effective mood stabilizing prophylatics/treatments for bipolar disorder, a highly heritable psychiatric disorder. Though it is not clear whether the mood stabilizing effects of these drugs act directly through GSK3 beta, it is a good candidate for mediating at least part of lithium's action, and is an aetiological candidate gene for the disease itself. Recently, a potential locus for bipolar disorder was reported on chromosome 3q, close to 3q13.37 where GSK3 beta maps. We conducted an association study to test the hypothesis that polymorphism of GSK3 beta is involved in susceptibility to bipolar disorder by examining association between GSK3 beta-gene polymorphisms and bipolar disorder. Of the five polymorphisms we examined, three were very rare in the study population and were not examined further. Neither of the remaining two polymorphisms we examined showed association with bipolar disorder. Thus, it is unlikely that the GSK3 beta-gene is a risk factor for bipolar disorder in our sample, but we cannot exclude the gene completely as other unknown polymorphisms in the gene may increase susceptibility. (c) 2005 Elsevier Ireland Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)243-245
Number of pages3
JournalNeuroscience Letters
Volume394
DOIs
Publication statusPublished - 2006

Keywords

  • manic depression
  • affective disorder
  • genetics
  • wnt
  • GSK3 beta
  • insulin
  • presenilin
  • Tau
  • lithium
  • allelic
  • SINGLE NUCLEOTIDE POLYMORPHISM
  • PROMOTER
  • ONSET
  • MECHANISM
  • ILLNESS
  • LITHIUM

Cite this

Association analysis of the glycogen synthase kinase-3 beta gene in bipolar disorder. / Nishiguchi, N ; Breen, G ; Russ, C ; St Clair, D ; Collier, D .

In: Neuroscience Letters, Vol. 394, 2006, p. 243-245.

Research output: Contribution to journalArticle

Nishiguchi, N ; Breen, G ; Russ, C ; St Clair, D ; Collier, D . / Association analysis of the glycogen synthase kinase-3 beta gene in bipolar disorder. In: Neuroscience Letters. 2006 ; Vol. 394. pp. 243-245.
@article{0f9821404dfe4d0f983d105b18205711,
title = "Association analysis of the glycogen synthase kinase-3 beta gene in bipolar disorder",
abstract = "Glycogen synthase kinase-3 beta (GSK3 beta) is a target of lithium as well as sodium valproate, both of which are effective mood stabilizing prophylatics/treatments for bipolar disorder, a highly heritable psychiatric disorder. Though it is not clear whether the mood stabilizing effects of these drugs act directly through GSK3 beta, it is a good candidate for mediating at least part of lithium's action, and is an aetiological candidate gene for the disease itself. Recently, a potential locus for bipolar disorder was reported on chromosome 3q, close to 3q13.37 where GSK3 beta maps. We conducted an association study to test the hypothesis that polymorphism of GSK3 beta is involved in susceptibility to bipolar disorder by examining association between GSK3 beta-gene polymorphisms and bipolar disorder. Of the five polymorphisms we examined, three were very rare in the study population and were not examined further. Neither of the remaining two polymorphisms we examined showed association with bipolar disorder. Thus, it is unlikely that the GSK3 beta-gene is a risk factor for bipolar disorder in our sample, but we cannot exclude the gene completely as other unknown polymorphisms in the gene may increase susceptibility. (c) 2005 Elsevier Ireland Ltd. All rights reserved.",
keywords = "manic depression, affective disorder, genetics, wnt, GSK3 beta, insulin, presenilin, Tau, lithium, allelic, SINGLE NUCLEOTIDE POLYMORPHISM, PROMOTER, ONSET, MECHANISM, ILLNESS, LITHIUM",
author = "N Nishiguchi and G Breen and C Russ and {St Clair}, D and D Collier",
year = "2006",
doi = "10.1016/j.neulet.2005.10.042",
language = "English",
volume = "394",
pages = "243--245",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Association analysis of the glycogen synthase kinase-3 beta gene in bipolar disorder

AU - Nishiguchi, N

AU - Breen, G

AU - Russ, C

AU - St Clair, D

AU - Collier, D

PY - 2006

Y1 - 2006

N2 - Glycogen synthase kinase-3 beta (GSK3 beta) is a target of lithium as well as sodium valproate, both of which are effective mood stabilizing prophylatics/treatments for bipolar disorder, a highly heritable psychiatric disorder. Though it is not clear whether the mood stabilizing effects of these drugs act directly through GSK3 beta, it is a good candidate for mediating at least part of lithium's action, and is an aetiological candidate gene for the disease itself. Recently, a potential locus for bipolar disorder was reported on chromosome 3q, close to 3q13.37 where GSK3 beta maps. We conducted an association study to test the hypothesis that polymorphism of GSK3 beta is involved in susceptibility to bipolar disorder by examining association between GSK3 beta-gene polymorphisms and bipolar disorder. Of the five polymorphisms we examined, three were very rare in the study population and were not examined further. Neither of the remaining two polymorphisms we examined showed association with bipolar disorder. Thus, it is unlikely that the GSK3 beta-gene is a risk factor for bipolar disorder in our sample, but we cannot exclude the gene completely as other unknown polymorphisms in the gene may increase susceptibility. (c) 2005 Elsevier Ireland Ltd. All rights reserved.

AB - Glycogen synthase kinase-3 beta (GSK3 beta) is a target of lithium as well as sodium valproate, both of which are effective mood stabilizing prophylatics/treatments for bipolar disorder, a highly heritable psychiatric disorder. Though it is not clear whether the mood stabilizing effects of these drugs act directly through GSK3 beta, it is a good candidate for mediating at least part of lithium's action, and is an aetiological candidate gene for the disease itself. Recently, a potential locus for bipolar disorder was reported on chromosome 3q, close to 3q13.37 where GSK3 beta maps. We conducted an association study to test the hypothesis that polymorphism of GSK3 beta is involved in susceptibility to bipolar disorder by examining association between GSK3 beta-gene polymorphisms and bipolar disorder. Of the five polymorphisms we examined, three were very rare in the study population and were not examined further. Neither of the remaining two polymorphisms we examined showed association with bipolar disorder. Thus, it is unlikely that the GSK3 beta-gene is a risk factor for bipolar disorder in our sample, but we cannot exclude the gene completely as other unknown polymorphisms in the gene may increase susceptibility. (c) 2005 Elsevier Ireland Ltd. All rights reserved.

KW - manic depression

KW - affective disorder

KW - genetics

KW - wnt

KW - GSK3 beta

KW - insulin

KW - presenilin

KW - Tau

KW - lithium

KW - allelic

KW - SINGLE NUCLEOTIDE POLYMORPHISM

KW - PROMOTER

KW - ONSET

KW - MECHANISM

KW - ILLNESS

KW - LITHIUM

U2 - 10.1016/j.neulet.2005.10.042

DO - 10.1016/j.neulet.2005.10.042

M3 - Article

VL - 394

SP - 243

EP - 245

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

ER -